期刊文献+

局部晚期膀胱癌术前动脉灌注新辅助化疗的安全性与疗效分析 被引量:4

Safety and efficacy of intra-arterial infusion neoadjuvant chemotherapy for local advanced bladder cancer
原文传递
导出
摘要 目的探讨根治性膀胱切除术前动脉灌注化疗治疗局部晚期膀胱癌的安全性与疗效。方法局部晚期膀胱癌患者(T2~T4a)19例,采用2-脱氧2,2-盐酸二氟脱氧胞苷(β-异构体)与(顺)二氨二氯铂(GC)方案髂内动脉灌注化疗1~3次,随后行膀胱根治性切除术或经尿道膀胱肿瘤电切术,2例肿瘤缩小者拒绝手术治疗,2例经术前评价不能承受手术治疗。统计学分析比较化疗前后患者血自细胞、红细胞、血小板水平,肝肾功能,肿瘤大小、分期及病理分级的变化。结果19例患者化疗前后白细胞计数分别为(6.63±2.58)×10^9/L、(5.12±2.91)×10^9/L,差异无统计学意义(P=0.13);红细胞计数分别为(4.41±0.52)×10^12/L、(3.92±0.42)×10^12/L,差异有统计学意义(P=0.00);血小板计数分别为(220.50±59.86)×10^9/L、(157.05±56.72)×10^9/L,差异有统计学意义(P=0.001);丙氨酸氨基转移酶(ALT)分别为(20.00±8.31)、(26.88±17.04)U/L,差异无统计学意义(P=0.08);SCr分别为(95.82±14.57)、(88.04±17.76)μmol/L,差异无统计学意义(P=0.06);肿瘤最大径分别为(3.72±1.23)、(2.80±1.29)cm,差异有统计学意义(P=0.02)。13例根治性切除术患者中降期9例,临床分期与病理分期相符4例;化疗前后细胞分级符合者4例,Ⅰ级转为Ⅱ级者4例,Ⅱ级转Ⅲ级者4例,Ⅲ级转为Ⅱ级1例。结论GC方案动脉灌注新辅助化疗治疗局部晚期膀胱癌,患者耐受性好,未对化疗后手术治疗造成不良影响;多数患者出现肿瘤体积缩小,TNM分期降期;部分敏感患者可选择行保留膀胱的手术。 Objective To evaluate the safety and efficacy of intra-arterial infusion neoadjuvant chemotherapy in local advanced bladder cancer. Methods Nineteen cases with T2--T4a bladder cancer were enrolled in this study. Intra-arterial infusion chemotherapy with Gemcitabine and Cisplatin (GC)were performed for 1 to 3 cycles before radical cystectomy. Postoperative values of hematological parameters, maximum diameter of tumors, TNM(tumor,node and metastasis)stages and pathological grades were compared with preoperative parameters of the same case. Results Compared to the values before GC chemotherapy, WBC count showed no significant change post-operative, (6. 63 ±2.58) ×10^9/L vs(5.12±2.91) ×10^9/L(P=0.13);RBC(4. 41+_0. 52)×10^12/L vs(3. 92±0. 42)×10^12/L(P= 0.00) and platelet count(220.50±59.86)×10^9/L vs (157.05±56. 72)×10^9/L(P=0. 001)showed significant decrease;ALT did not show significant decrease(20. 00±8. 31 vs 26. 88±17.04 U/L,P=0.08);Creatitine also showed no significant change(95.82±14. 57 vs 88.04± 17. 76 μmol/L, P= 0.06) ; Maximum diameter of tumors decreased significantly(3.72± 1.23 vs 2. 80± 1.29 cm,P=0.02). Compared with clinical TNM stages, pathological TNM stages demonstrated significant decrease in 9 cases;While cell differentiation did not show decrease. Conclusions Intra-arterial infusion with GC regi men can reduce tumor size,decrease TNM stages,while not causing significant adverse impact to radi cal cystectomy. Bladder-spare treatment is an option for chemotherapy sensitive cases.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2009年第10期681-684,共4页 Chinese Journal of Urology
关键词 膀胱肿瘤 化学疗法 辅助 Bladder neoplasms Carcinoma Chemotherapy, adjuvant
  • 相关文献

参考文献13

  • 1Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol, 2006, 57:133- 144.
  • 2余绍龙,周芳坚,秦自科,韩辉,刘卓炜,王斌,王欢,李永红.移行细胞癌盆腔复发动脉化疗的疗效观察[J].中华泌尿外科杂志,2005,26(10):689-691. 被引量:4
  • 3刘卓炜,周芳坚,余绍龙,秦自科,韩辉,王斌,王欢,李永红.动脉化疗治疗低分化膀胱移行细胞癌的初步临床疗效[J].癌症,2004,23(z1):1517-1519. 被引量:3
  • 4vonder Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol, 2000, 18: 3068-3077.
  • 5yon der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 2005, 23: 4602-4608.
  • 6Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta analysis of individual patient data advanced bladder cancer. Eur Urol, 2005, 48: 202-205.
  • 7Winquist E, Kirchner TS, Segal R, et al, Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the blad der: a systematic review and recta-analysis. J Urol, 2004, 171 :561-569.
  • 8Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cysteetorny alone for locally advanced bladder cancer. N Engl J Med, 2003, 349: 859-866.
  • 9Herchenhorn D, Dienstmann R, Peixoto FA, et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol, 2007, 33: 630- 638.
  • 10牛亦农,邢念增,郭应禄.腹腔镜根治性膀胱切除与尿流改道术临床进展[J].中华临床医师杂志(电子版),2007,1(7):3-6. 被引量:4

二级参考文献38

  • 1刘卓炜,周芳坚,余绍龙,秦自科,韩辉,王斌,王欢,李永红.动脉化疗治疗低分化膀胱移行细胞癌的初步临床疗效[J].癌症,2004,23(z1):1517-1519. 被引量:3
  • 2李鸣,李宁忱,黄真,那彦群.浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察[J].中华泌尿外科杂志,2004,25(10):662-664. 被引量:20
  • 3余绍龙,周芳坚,秦自科,韩辉,刘卓炜,王斌,王欢,李永红.移行细胞癌盆腔复发动脉化疗的疗效观察[J].中华泌尿外科杂志,2005,26(10):689-691. 被引量:4
  • 4邢念增,阎勇,李建兴,康宁,张军晖,牛亦农,武治津,郭应禄.原位T型回肠新膀胱的手术体会(附5例报告)[J].现代泌尿外科杂志,2006,11(3):180-180. 被引量:8
  • 5[1]Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer [J]. J Urol, 2000, 163:73 -78.
  • 6[2]Kubota Y, Kakizaki H, Numasana K, et al. Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer [J]. Eur Urol, 1989, 16:189 - 194.
  • 7[3]Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer:grade is the primary determinant for risk of muscleinvasion [J]. J Urol, 1991, 146:28 - 31.
  • 8[4]Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer [J]. Minerva Urol Nefrol, 2004, 56:65 -72.
  • 9[5]Birch RP, Harland SJ. The pT1G3 bladder tumor [J]. BrJ Urol, 1989, 64:109 - 116.
  • 10[6]Lamm DL, Griffith JG. Intravesical therapy: does it alter the natural history of superficial bladder cancer? [J]. Semin Urol 1992, 10:39 -44.

共引文献8

同被引文献63

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部